Effects of Exercise Snacks on Physical Health and Cognitive Function in Individuals With Intellectual Disabilities

August 6, 2026 updated by: University of Macau
Intellectual disability (ID) is a neurodevelopmental disorder accompanied by sedentary lifestyles, which worsens cognitive function and physical health. Short-duration high-frequency exercise snacks (ES) may be a feasible intervention for adults with ID. This randomized controlled crossover study aims to explore the acute effects of exercise snacks, conventional HIIT and daily routine control on cognitive function, stereotyped behaviors and prefrontal cortex activation in adults with mild to moderate ID. All participants will receive three intervention conditions with a 1-week washout period between each trial. Neurophysiological indicators including EEG and heart rate variability will be measured to reveal the underlying mechanisms.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Background:

Adults with intellectual disability commonly maintain sedentary daily routines, resulting in progressive decline in physical fitness and cognitive performance. Traditional long-duration exercise interventions are difficult to implement for this population due to behavioral and cognitive limitations. Exercise snacks, consisting of repeated ultra-short exercise bursts, are easy to carry out and show promising benefits for cognition.

Methods:

A randomized controlled crossover design will be adopted. Twenty-four adults aged 18-35 years with mild to moderate ID will complete three conditions in random sequence: no-exercise control, high-intensity interval training (HIIT), and exercise snacks (ES). A 1-week washout interval separates different interventions.

Intervention protocols:

  1. Control: maintain habitual daily activities.
  2. HIIT: one afternoon session, 10 sets of 6-second high-knee exercise with 9 seconds rest.
  3. ES: morning and afternoon sessions every day; each session contains 5 sets of 6-second high-knee exercise with 9 seconds rest.

Main measurements include prefrontal cortex activation via EEG, cognitive function, stereotyped behaviors, and heart rate variability. Repeated-measures statistical models will be used for data analysis.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
24

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
    • Zhejiang
      • Hangzhou, Zhejiang, China
        • Hangzhou First Social Welfare Institute
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Aged 18-35 years old;
  2. Clinically diagnosed mild to moderate intellectual disability;
  3. Able to follow simple verbal instructions and complete exercise protocols;
  4. No contraindications for moderate physical activity confirmed by medical inquiry;
  5. Participants or legal guardians provide written informed consent;
  6. Maintain stable daily routine and do not participate in other structured exercise programs during the trial.

Exclusion Criteria:

  1. Severe physical disabilities, orthopedic injury or neurological disorders that restrict movement;
  2. History of cardiovascular disease, uncontrolled hypertension or other exercise contraindications;
  3. Current psychiatric medication that significantly affects motor or cognitive function;
  4. Inability to cooperate with EEG and physiological signal collection;
  5. Pregnancy;
  6. Participation in other interventional studies within the past 3 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Arm 1
Participants maintain their usual daily activities without additional prescribed exercise. Daily physical activity will be recorded throughout the intervention period.
Experimental: Arm 2（Exercise Snacks）
Twice-daily short-bout exercise snacks. Each session includes 5 sets of 6-second high-knee exercise with 9 seconds rest between sets.
Behavioral: Exercise Snacks
Twice-daily short-bout exercise snacks. Each session includes 5 sets of 6-second high-knee exercise with 9 seconds rest between sets.
Experimental: Arm 3（High-Intensity Interval Training ）
One intervention session scheduled in the afternoon. The protocol consists of 10 sets of 6-second high-knee exercise, separated by 9 seconds of rest between sets.
Behavioral: High-Intensity Interval Training
Acute high-intensity interval training protocol: 10 × 6 s high-knee exercise with 9 s rest between sets, completed in a single afternoon session.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Changes in cognitive function assessed by cognitive test battery
Time Frame: Baseline and immediately after the acute intervention
Changes in cognitive performance measured after each intervention condition, including attention and executive function.
Baseline and immediately after the acute intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Prefrontal cortex activation measured by electroencephalography (EEG)
Time Frame: Baseline and immediately after the acute intervention
Changes in prefrontal cortical brain activity indexed by EEG power spectrum during cognitive tasks.
Baseline and immediately after the acute intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Macau

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Zhaowei Kong, PhD, University of Macau

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 16, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 18, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 8, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 29, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BSE-1553-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data will be available upon reasonable request to the corresponding investigator after study completion and main publication. Data sharing will be subject to a formal data use agreement.

IPD Sharing Time Frame

Data and supporting materials will be available starting 6 months following the publication of primary study outcomes, and remain accessible for up to 5 years thereafter.

IPD Sharing Access Criteria

Qualified researchers who submit a methodologically sound research proposal. Requests need to be sent to the corresponding investigator and a data use agreement must be signed.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings